Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Non-Current Debt (2024 - 2025)

Humacyte has reported Non-Current Debt over the past 2 years, most recently at $17.7 million for Q3 2025.

  • Quarterly results put Non-Current Debt at $17.7 million for Q3 2025, down 71.55% from a year ago — trailing twelve months through Sep 2025 was $17.7 million (down 71.55% YoY), and the annual figure for FY2024 was $64.2 million, changed.
  • Non-Current Debt for Q3 2025 was $17.7 million at Humacyte, down from $66.4 million in the prior quarter.
  • Over the last five years, Non-Current Debt for HUMA hit a ceiling of $66.4 million in Q2 2025 and a floor of $17.7 million in Q3 2025.